How Chapman was paid
$15M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Steven ChapmanChief Executive Officer and President | $853,710 | $12,979,558 | $1,114,151 | $9,900 | $14,957,319 |
| Michael BrophyChief Financial Officer | $562,794 | $4,500,844 | $390,175 | $6,209 | $5,460,022 |
| John FeskoPresident, Chief Business Officer | $504,652 | $4,186,634 | $351,604 | $9,900 | $5,052,790 |
| Solomon MoshkevichPresident, Clinical Diagnostics | $504,652 | $4,500,844 | $351,604 | $9,900 | $5,367,000 |
| Matthew RabinowitzExecutive Chairman | $426,434 | $10,383,434 | $473,514 | — | $11,283,382 |
What changed and why
- $2,306.1MTotal revenues reached $2,306.1 million representing approximately 36% growth over 2024.
- $15MCEO total compensation increased to $14,957,319 in 2025 from $13,032,674 in 2024.
- 95.8%Stockholders approved executive compensation with approximately 95.8% support at the prior annual meeting.
- 94%94% of the CEO total compensation was delivered as variable, at-risk compensation.
- $1,493.2MGross profit improved to $1,493.2 million compared to $1,023.2 million in 2024.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.